Establishing Muscle Impedance Parameters With Electrical Impedance Myography
NCT ID: NCT03633318
Last Updated: 2020-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
31 participants
OBSERVATIONAL
2018-06-19
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Natalizumab in Inclusion Body Myositis (IBM)
NCT02483845
Sporadic Inclusion Body Myositis Natural History Study
NCT05046821
Immune Abnormalities in Sporadic Inclusion Body Myositis
NCT00030212
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
NCT01925209
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT02250443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IBM Group
Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
electrical impedance myography (EIM)
EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
Control Group
Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
electrical impedance myography (EIM)
EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
electrical impedance myography (EIM)
EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy controls will be age and gender-matched to the enrolled IBM patients.
Exclusion Criteria
* Patients with chronic kidney disease on hemodialysis
* Patients with active cancer on chemotherapy or radiotherapy
* Patients with severe disease who are already wheel-chair bound
46 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bhaskar Roy, MBBS
Role: PRINCIPAL_INVESTIGATOR
Yale School of Medicine: Department of Neurology
Richard J Nowak, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Yale School of Medicine: Department of Neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale Physicians Building
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2000023035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.